News
The server encountered an error and could not complete your request. If the problem persists, please contact us using the ...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for ...
Biocon Ltd's arm, Biocon Biologics Ltd, has received European Commission authorisation for its Vevzuo and Evfraxy biosimilars ...
CuraTeQ Biologics, a unit of Aurobindo Pharma, has received EU approval to market Dazublys, its trastuzumab biosimilar for ...
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, secured European Commission approval for its trastuzumab biosimilar, ...
2d
GlobalData on MSNVertex wins European approval for Alyftrek, bolstering cystic fibrosis strongholdWith its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis ...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that ...
1d
NDTV Profit on MSNBiocon Biologics Granted Marketing Authorisation By European Commission For Bone Disease MedicinesBiocon Biologics was granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases.
The European Medicines Agency has begun a review of medicines to treat alcohol dependency that contain sodium oxybate, it ...
Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the ...
CuraTeQ Biologics, a wholly owned subsidiary of the company dedicated to oncology and immunology segments, has received authorisation from the European authorities.
Uruguay’s MSP has tasked a working group and a proposal has been created by the Faculty of Chemistry at the University of Uruguay.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results